Kamada Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 4/6

KamadaDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -29.7% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsatzerlöse sind gewachsen mit einer durchschnittlichen Rate von 3.4% pro Jahr. Kamada Die Eigenkapitalrendite des Unternehmens beträgt 6.2%, und die Nettomargen liegen bei 9.9%.

Wichtige Informationen

-29.7%

Wachstumsrate der Gewinne

-36.6%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	-24.5%
Wachstumsrate der Einnahmen	3.4%
Eigenkapitalrendite	6.2%
Netto-Marge	9.9%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business

Nov 20

Recent updates

Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business

Nov 20

Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality

Mar 14

Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%

Dec 30

Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year

Dec 22

Is Kamada (TLV:KMDA) Using Too Much Debt?

Jan 26

We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed

Dec 16

Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%

Mar 01

Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?

Feb 08

Is Weakness In Kamada Ltd. (TLV:KMDA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Jan 21

Kamada Ltd. (TLV:KMDA) Shares Could Be 42% Below Their Intrinsic Value Estimate

Jan 03

How Many Kamada Ltd. (TLV:KMDA) Shares Have Insiders Sold, In The Last Year?

Dec 15

Are Kamada's (TLV:KMDA) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 29

Aufschlüsselung der Einnahmen und Ausgaben

Wie Kamada Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

TASE:KMDA Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 24	158	16	35	14
30 Jun 24	155	15	34	14
31 Mar 24	150	12	33	13
31 Dec 23	143	8	32	12
30 Sep 23	152	6	32	12
30 Jun 23	146	3	31	12
31 Mar 23	132	-2	30	11
31 Dec 22	129	-2	29	12
30 Sep 22	115	-10	27	11
30 Jun 22	106	-12	24	11
31 Mar 22	107	-7	22	11
31 Dec 21	104	-2	20	9
30 Sep 21	104	4	19	9
30 Jun 21	116	12	19	10
31 Mar 21	125	15	17	11
31 Dec 20	133	17	17	12
30 Sep 20	134	21	16	12
30 Jun 20	132	20	16	12
31 Mar 20	134	23	16	11
31 Dec 19	127	22	16	11
30 Sep 19	143	35	16	10
30 Jun 19	125	26	15	9
31 Mar 19	124	26	14	8
31 Dec 18	114	22	14	8
30 Sep 18	102	11	14	7
30 Jun 18	110	13	15	8
31 Mar 18	109	12	15	9
31 Dec 17	103	7	15	10
30 Sep 17	91	-1	15	11
30 Jun 17	88	-2	15	12
31 Mar 17	74	-8	14	12
31 Dec 16	77	-7	14	13
30 Sep 16	79	-4	16	12
30 Jun 16	76	-8	15	13
31 Mar 16	76	-8	15	12
31 Dec 15	70	-11	15	12
30 Sep 15	69	-11	14	11
30 Jun 15	70	-9	14	11
31 Mar 15	67	-15	14	12
31 Dec 14	71	-13	15	12
30 Sep 14	71	-13	10	16
30 Jun 14	71	-10	9	15
31 Mar 14	71	-1	9	12
31 Dec 13	71	0	10	11

Qualität der Erträge: KMDA hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: KMDADie aktuellen Gewinnspannen (9.9%) sind höher als im letzten Jahr (4.1%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: KMDADie Erträge des Unternehmens sind in den letzten 5 Jahren um 29.7% pro Jahr zurückgegangen.

Beschleunigtes Wachstum: KMDADas Gewinnwachstum des Unternehmens im letzten Jahr (154.7%) übertrifft seinen 5-Jahres-Durchschnitt (-29.7% pro Jahr).

Erträge im Vergleich zur Industrie: KMDA Das Gewinnwachstum im vergangenen Jahr (154.7%) übertraf das der Branche Biotechs 4% .

Eigenkapitalrendite

Hohe Eigenkapitalrendite: KMDADie Eigenkapitalrendite des Unternehmens (6.2%) wird als niedrig angesehen.

Kamada Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business

Third quarter 2024 earnings released: EPS: US$0.07 (vs US$0.07 in 3Q 2023)

Kamada Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Second quarter 2024 earnings released: EPS: US$0.08 (vs US$0.04 in 2Q 2023)

Kamada Ltd. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings released

Recent updates

Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business

Third quarter 2024 earnings released: EPS: US$0.07 (vs US$0.07 in 3Q 2023)

Kamada Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Kamada Ltd., Annual General Meeting, Dec 11, 2024

Second quarter 2024 earnings released: EPS: US$0.08 (vs US$0.04 in 2Q 2023)

Kamada Ltd. Provides Earnings Guidance for the Year 2024

Kamada Ltd. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings released

Kamada Ltd. Raises Earnings Guidance for the Year 2024

Kamada Ltd. to Report Q1, 2024 Results on May 08, 2024

Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: US$0.17 (vs US$0.052 loss in FY 2022)

Kamada Ltd. Provides Revenue Guidance for the Year 2024

Kamada Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%

Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year

Investor sentiment improves as stock rises 19%

Third quarter 2023 earnings released: EPS: US$0.07 (vs US$0.011 in 3Q 2022)

Kamada Ltd., Annual General Meeting, Dec 28, 2023

Kamada Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Kamada Ltd. Announces Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

New minor risk - Shareholder dilution

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.09 loss in 2Q 2022)

Kamada Ltd. to Report Q2, 2023 Results on Aug 16, 2023

First quarter 2023 earnings released: US$0.04 loss per share (vs US$0.04 loss in 1Q 2022)

Kamada Ltd. announced that it expects to receive $59.85 million in funding from First Israel Mezzanine Investors Ltd.

Kamada Ltd. to Report Q1, 2023 Results on May 24, 2023

Kamada Ltd. Announces Receipt of Marketing Authorization for Glassia for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

Kamada Ltd. Announces U.S. FDA Approval of Its Application to Manufacture CYTOGAM At the Company’s Facility in Israel

Full year 2022 earnings released: US$0.05 loss per share (vs US$0.05 loss in FY 2021)

Is Kamada (TLV:KMDA) Using Too Much Debt?

Kamada Ltd. Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® At the Company’s Facility in Israel

Kamada Ltd. Appoints Uri Botzer as Members of Board of Directors

Kamada Announces Planned Transition of Chaime Orlev, Chief Financial Officer, Effective March 15, 2023

We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed

Third quarter 2022 earnings released: EPS: US$0.01 (vs US$0.02 loss in 3Q 2021)

Kamada Ltd. Provides Revenue Guidance for the Fiscal Year 2022

Kamada Ltd. to Report Q3, 2022 Results on Nov 22, 2022

High number of new directors

Kamada Ltd., Annual General Meeting, Dec 22, 2022

Kamada Ltd. Updates on Recent Progress Achieved in Ongoing Pivotal Phase 3 InnovAATe Clinical Trial

Second quarter 2022 earnings released: US$0.09 loss per share (vs US$0.02 profit in 2Q 2021)

Kamada Ltd. Provides Earnings Guidance for the Second Half of Year and Full Year 2022

Kamada Ltd. to Report Q2, 2022 Results on Aug 17, 2022

Kamada Ltd. Provides Earnings Guidance for the Full Year of 2022

First quarter 2022 earnings released: US$0.04 loss per share (vs US$0.06 profit in 1Q 2021)

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022

Kamada Ltd. to Report Q1, 2022 Results on May 17, 2022

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Kamada Ltd. to Report Q4, 2021 Results on Mar 15, 2022

Kamada Ltd. Acquires Portfolio of Four Plasma-Derived Hyperimmune Commercial Products from Saol Therapeutics

Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint

Kamada Ltd.(TASE:KMDA) dropped from TA-125 Index

Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.08 in 2Q 2020)

Kedrion Biopharma and Kamada Ltd. Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

First quarter 2021 earnings released: EPS US$0.06 (vs US$0.12 in 1Q 2020)

Kamada Ltd. (TASE:KMDA) completed the acquisition of Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc.

New 90-day low: ₪20.12

Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%

Full year 2020 earnings released: EPS US$0.39 (vs US$0.55 in FY 2019)

Revenue misses expectations

Investor sentiment improved over the past week

New 90-day high: ₪24.74

Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?

Kamada Ltd. to Report Q4, 2020 Results on Feb 10, 2021

Kamada Ltd. (TASE:KMDA) entered into an agreement to acquire Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc. for $1.6 million.